<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596670</url>
  </required_header>
  <id_info>
    <org_study_id>2020KT112</org_study_id>
    <nct_id>NCT04596670</nct_id>
  </id_info>
  <brief_title>68Ga-ICAM-1pep PET/CT in Cancer Patients</brief_title>
  <official_title>68Ga-ICAM-1pep PET/CT Imaging of Tumor Responses to Radiotherapy in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label positron emission tomography/computed tomography (PET/CT) study to&#xD;
      investigate the clinical predictive value of 68Ga-ICAM-1pep in metastatic cancer patients&#xD;
      receiving radiotherapy. A single dose of 2.96 MBq/kg body weight of 68Ga-ICAM-1pep will be&#xD;
      injected intravenously. The visual and semiquantitative methods will be used to assess the&#xD;
      PET/CT images.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiotherapy has a systemic inhibitory effect on non-irradiated lesions (abscopal effect) in&#xD;
      addition to local antitumor effects, and currently no biomarkers are used for the prediction&#xD;
      of the abscopal effect of radiotherapy in standard clinical practice. Our recent preclinical&#xD;
      studies identified ICAM-1 as a potential predictive biomarker for the radiotherapy-induced&#xD;
      abscopal effect. In this clinical trial, we aim to investigate whether the ICAM-1-targeting&#xD;
      radiotracer 68Ga-ICAM-1pep could be used for PET imaging of tumor responses to radiotherapy&#xD;
      in cancer patients. PET/CT imaging of 68Ga-ICAM-1pep will be performed in patients before and&#xD;
      after radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 25, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitate the standardized uptake values (SUVs) of 68Ga-ICAM-1pep at baseline.</measure>
    <time_frame>At baseline</time_frame>
    <description>Perform PET/CT imaging using 68Ga-ICAM-1pep before radiotherapy.The semiquantitative analysis will be performed by the same nuclear medicine physician for all cases, and the standardized uptake values (SUVs) of 68Ga-ICAM-1pep in the tumor lesions will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize changes in the standardized uptake values (SUVs) of 68Ga-ICAM-1pep during radiotherapy.</measure>
    <time_frame>3 to 4 weeks after beginning of radiotherapy</time_frame>
    <description>Perform PET/CT imaging using 68Ga-ICAM-1pep after radiotherapy. The semiquantitative analysis will be performed by the same nuclear medicine physician for all cases, and the standardized uptake values (SUVs) of 68Ga-ICAM-1pep in the tumor lesions will be measured. The SUVs of 68Ga-ICAM-1pep in the tumor lesions after radiotherapy will be compared with that at the baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-ICAM1-1pep PET/CT in cancer patients before radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer patients who have not undergone radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.&#xD;
Interventions:&#xD;
Drug: 68Ga-ICAM-1pep Device: PET/CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68Ga-ICAM1-1pep PET/CT in cancer patients after radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer patients post-radiotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-ICAM-1pep in one dose intravenously and then undergo PET/CT scan 1 h later.&#xD;
Interventions:&#xD;
Drug: 68Ga-ICAM-1pep Device: PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-ICAM-1pep</intervention_name>
    <description>68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.</description>
    <arm_group_label>68Ga-ICAM1-1pep PET/CT in cancer patients after radiotherapy</arm_group_label>
    <arm_group_label>68Ga-ICAM1-1pep PET/CT in cancer patients before radiotherapy</arm_group_label>
    <other_name>68Ga-CD54pep</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-80 years old;&#xD;
&#xD;
          2. ECOG score 0 or 1 point;&#xD;
&#xD;
          3. Patients with suspected or confirmed lung cancer, esophagus cancer, cervical cancer or&#xD;
             other cancers who are suggested by the clinicians to conduct PET/CT imaging for tumor&#xD;
             diagnosis or staging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing;&#xD;
&#xD;
          2. Severe hepatic or renal dysfunction;&#xD;
&#xD;
          3. Low WBC (less than 3 x 10^9/L);&#xD;
&#xD;
          4. Unable to comply with the PET/CT imaging procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi Yang, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hua Zhu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ting Zhang</last_name>
    <phone>+8610-82802893</phone>
    <email>zhangt0183@bjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shunlian Zhou</last_name>
      <email>zhoushunlian@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhu</investigator_full_name>
    <investigator_title>Principal Investigator and Vice Director</investigator_title>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>ICAM-1</keyword>
  <keyword>68Ga labeling</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

